Welcome to the e-CCO Library!

P673: Microbial diversity in newly diagnosed treatment naïve Inflammatory Bowel Disease patients
Year: 2021
Source: ECCO'21 Virtual
Authors: Ellul , S.(1);Rausch , P.(2);Pisani , A.(3);Bang , C.(2);ellul , P.(3);Franke , A.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P673: The safety of rapid versus standard infliximab infusions in children with inflammatory bowel disease: a multi-centre retrospective cohort study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Jagt, J.(1,2)*;Galestin, S.(3);Benninga, M.(1);de Boer, N.(4);de Meij, T.(1);
Created: Friday, 14 July 2023, 11:12 AM
P673: Vedolizumab dose escalation as a way of recapturing response in patients with inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Sierra Morales1,2*, S. Birdi1, M.A. Samaan1, C. Brown-Clarke1, J. Duncan1, A. Stanton1, I. Koumoutsos1, S. Anderson1, S. Ray1, J. Mawdsley1, J. Sanderson1, P.M. Irving1

Created: Thursday, 21 February 2019, 9:14 AM
P674 Monitoring posologic change in adalimumab intensification dosing regimen from 40 mg every week to 80 mg every other week
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M.T. Diz Lois Palomares1, Á. Porta Sánchez2, L. Elberdin Pazos2, B. González Conde1, M. Outeda Macías2, M.T. Vázquez Rey1, A. Guerrero Montañés1, E. Estévez Prieto1

Created: Thursday, 30 January 2020, 10:12 AM
P674: Blood thiopurine level, anti-TNF drug level and body composition parameters in inflammatory bowel diseases patients: a cross-sectional study in a Hungarian IBD centre
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

K. Szántó1, A. L. Szíjártó2, D. Kata3, I. Földesi3, Z. A. Mezei4, A. Fábián1, A. Bálint1, R. Bor1, K. Farkas1, Á. Milassin1, M. Rutka1, Z. Szepes1, F. Nagy1, T. Bubán5, S. Lovas6, K. Palatka6, T. Molnár1

Created: Friday, 22 February 2019, 9:41 AM
P674: Clinical characteristics and management of Crohn’s disease in patients with residual disease after surgery compared with curative surgery: Results from PRACTICROHN study
Year: 2018
Source: ECCO '18 Vienna
Authors:

E. Domènech1*, M.D. Martín Arranz2, M. Iborra3, V. García4, A. Gutiérrez5, C. Taxonera6, L. Cea-Calvo7, C. Romero7, M. Barreiro-de Acosta8, B. Juliá7

Created: Thursday, 21 February 2019, 9:14 AM
P674: Definition of a microbial signature as a predictor of anti-TNFα treatment response
Year: 2021
Source: ECCO'21 Virtual
Authors: Oliver, L.(1);Busquets, D.(2);Amoedo, J.(1);Ramió-Pujol, S.(1);Malagón, M.(1);Serrano, M.(1);Bahí, A.(3);Lluansí, A.(3);Gilabert, P.(4);Miquel-Cusachs, J.O.(2);Sàbat, M.(5);Guardiola, J.(4);Serra-Pagès, M.(1);Garcia-Gil, J.(6);Aldeguer, X.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P674: Potential utility of therapeutic drug monitoring of adalimumab in predicting short-term mucosal healing and histologic remission in paediatric Crohn's disease patients
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Kang B.*1, Lee K.1, Choe B.-H.2, Choe Y.H.1

Created: Wednesday, 20 February 2019, 10:36 AM
P674: Predictors of response to biologics in Crohn's Diseases: A population-based study from the epi-IIRN
Year: 2022
Source: ECCO'22
Authors: Atia, O.(1); Lujan, R.(1); Greenfeld, S.(2); Kariv, R.(3); Matz, E.(4);Dotan, I.(5); Nevo, D.(6); Turner, D.(1);
Created: Friday, 11 February 2022, 3:56 PM
P674: Ustekinumab is the preferred biological agent in IBD patients with hidradenitis suppurativa failing anti-TNF therapy : results from a real-life multicenter cohort
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Verstockt., B.(1,2)*;Vieujean, S.(3);Truyens, M.(4,5);Julsgaard, M.(6);Pugliese, D.(7);Aslan, D.(1);Prokopic, M.(8);Lim, S.(9);Viganò, C.(10);Festa, S.(11);Ramos, L.(12);Garciá, M.J.(13);Plaza, R.(14);Noviello, D.(15);Savarino, E.(16);Drobne, D.(17);Imperatore, N.(18);Ribaldone, D.G.(19);Van Dongen, J.(20);Teich, N.(21);Wahed, M.(22);Barberio, B.(23);Goren, I.(24,25);
Created: Friday, 14 July 2023, 11:12 AM
P675 CT-Scout platform, the digital solution to boost patient recruitment in inflammatory bowel disease clinical trials: A multicentre prospective observational comparative study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

Y. Bouhnik1, X. Hebuterne2, M. Raith3, A. Amiot4, C. Tanasa Stefanescu1, D. Laharie5, X. Roblin6, A. Bourreille7, S. Nancey8, N. Sabbah9, L. Peyrin Biroulet10

Created: Thursday, 30 January 2020, 10:12 AM
P675: Associations between Inflammatory Bowel Disease, social isolation, and mortality: evidence from UK Biobank cohort study
Year: 2022
Source: ECCO'22
Authors: Chen, J.(1);Geng, J.(1);Wang, J.(2);Fu, T.(2);Sun, Y.(1);Chen, H.(3);Chen, X.(2);Wang, X.(2);Hesketh, T.(1);
Created: Friday, 11 February 2022, 3:56 PM
P675: Flavonoid-degrading bacteria have central positions in correlation network analysis in patients with Inflammatory Bowel Disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Pisani, A.(1);Rausch, P.(2);Ellul, S.(3);Bang, C.(2);Tabone, T.(1);Marantidis Cordina, C.(4);Zahra, G.(5);Ellul, P.(1);Franke, A.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P675: Follow-up ileocolonoscopy is underused in Crohn’s disease patients after ileocecal resection despite higher total and inpatient health care costs compared with controls without resection
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Schoepfer1, S. Vavricka2*, B. Brüngger3, E. Blozik3, J. Celeiro4, T. Greuter2, C. Bähler3

Created: Thursday, 21 February 2019, 9:14 AM
P675: Infliximab biosimilar CT-P13 therapy is effective in maintaining clinical remission in Crohn's disease and ulcerative colitis – 54 week data
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Molnár T.*1, Farkas K.1, Rutka M.1, Ferenci T.2, Nagy F.1, Bálint A.1, Bor R.1, Milassin A.1, Fábián A.1, Végh Z.3, Kürti Z.3, Lakatos P.L.3, Szepes Z.1

Created: Wednesday, 20 February 2019, 10:36 AM
P675: Real world evidence of tofacinitib in ulcerative colitis: short and long-term effectiveness, safety and impact of extraintestinal manifestations and immunomediated diseases
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Chaparro Sanchez, M.(1)*;Acosta, D.(1);Rodríguez, C.(2);Mesonero, F.(3);Vicuña, M.(2);Barreiro-de Acosta, M.(4);Fernández-Clotet, A.(5);Hernández Martínez, Á.(6); Arroyo, M.(7);Vera, I.(8); Ruiz-Cerulla, A.(9);Sicilia, B.(10);Cabello Tapia, M.J.(11);Muñoz Villafranca, C.(12);Castro-Poceiro, J.(13);Martínez Cadilla, J.(14);Sierra-Ausín, M.(15);Vázquez Morón, J.M.(16);Montil Miguel, E.(17);Bermejo, F.(18);Royo, V.(19);Calafat, M.(20);González-Muñoza, C.(21);Leo Carnerero, E.(22);Manceñido Marcos, N.(23);Torrealba, L.(24); Alonso-Galán, H.(25);Benítez, J.M.(26);Ber Nieto, Y.(27);Diz-Lois Palomares, M.T.(28);García, M.J.(29);Muñoz, J.F.(30);Armesto González, E.M.(31);Calvet, X.(32); Hernández-Camba, A.(33);Madrigal Domínguez, R.E.(34);Menchén, L.(35);Pérez Calle, J.L.(36);Piqueras, M.(37);Gisbert, J.P.(1);
Created: Friday, 14 July 2023, 11:12 AM
P675: The relationship between gender, severity of disease, treatment type, and employment outcome in patients with inflammatory bowel disease in Israel
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

T. Naftali*1,2, A. Ein Dor Abarbanel3, N. Ruhimovich2, A. Bar-Gil Shitrit4, F. Sklerovsky-Benjaminov1,2, H. Shirin1,3, S. Matalon1,3, T. Ziv Baran5, E. Broide1,3

Created: Friday, 22 February 2019, 9:41 AM
P676 Faecal monitoring is useful in monitoring treatment response in anti-TNF-treated patients
Year: 2020
Source:

ECCO'20 Vienna

Authors:

K. Farkas1, K.J. Szántó1, D. Kata2, I. Földesi2, T. Ferenci3, M. Rutka1, D. Pigniczki1, R. Bor1, A. Fábián1, Z. Szepes1, F. Nagy1, T. Molnár1

Created: Thursday, 30 January 2020, 10:12 AM
P676: Burden of depression and anxiety among inflammatory bowel disease patients in a national cohort in Israel – Data from the EPI-IIRN
Year: 2022
Source: ECCO'22
Authors: Mekori - Domachevsky, E..(1);Ziv - Baran, T.(2);Loewenberg Weisband, Y.(3);Greenfeld, S.(4);Kariv, R.(4);Erez, M.(5);Friss, F.(6);Focht, G.(6);Turner, D.(6);Ben - Horin, S.(1);Kopylov, U.(1);
Created: Friday, 11 February 2022, 3:56 PM